We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

5 hedge funds and large institutions have $69 invested in Titan Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% less funds holding

Funds holding: 6 → 5 (-1)

47% less capital invested

Capital invested by funds: $130 → $69 (-$61)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
GWSA
Global Wealth Strategies & Associates
Colorado
-$3

TTNP Hedge Fund Activity: Q2 2026 in Review

5 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2026, worth a combined $69 — down 47% from $130 a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of TTNP and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Global Wealth Strategies & Associates, exiting entirely with an estimated $3 sold.

  • 5 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2026, down from 6 in Q1 2026.
  • Funds reported $69 of Titan Pharmaceuticals stock for Q2 2026, down 47% quarter-over-quarter.
  • 0 funds opened new Titan Pharmaceuticals positions in Q2 2026 and 1 closed out, a net change of -1 holder.
  • The largest Titan Pharmaceuticals seller in Q2 2026 was Global Wealth Strategies & Associates, an estimated $3 sold.

Based on aggregated 13F filings for Q2 2026.